View Older Stories View More Recent Stories
-
Clearmind Medicine partners with Polyrizon for intranasal MEAI formulation
-
Polyrizon partners with Clearmind to develop intranasal MEAI formulation
-
Clearmind Medicine completes treatment for second patient cohort in trial
-
Clearmind Medicine advances alcohol disorder drug trial, reports safety data
-
Clearmind Medicine completes second cohort enrollment in AUD trial
-
Clearmind Medicine receives NASDAQ minimum bid price deficiency notice
-
Clearmind Medicine doses first patient with CMND-100 at Hadassah Medical Center
-
Clearmind Medicine receives safety board approval for alcohol disorder trial
-
Clearmind Medicine (CMND) files for 5.78M share offering by selling stockholders
-
Clearmind Medicine enrolls first patient at Tel Aviv medical center
-
Clearmind Medicine receives approval to continue phase I trial
-
SciSparc files Israeli patent for depression treatment combination therapy
-
Clearmind Medicine Accelerate FDA-Approved Alcohol Use Disorder Clinical Trial by Activating Fifth Elite Global Medical Site
-
Clearmind Medicine reports positive phase I/IIa trial results for AUD treatment
-
Clearmind Medicine files Israeli patent for depression treatment
-
Clearmind Medicine completes first cohort in alcohol disorder trial
-
Clearmind files patent in South Korea for MEAI depression treatment
-
Clearmind Medicine files U.S. patent application for cocaine addiction therapy
-
Clearmind Medicine completes first patient cohort in alcohol disorder trial
-
Clearmind Medicine names Mary-Elizabeth Gifford chief of global impact
-
Clearmind Medicine completes first cohort enrollment in alcohol disorder trial
-
SciSparc and Clearmind publish patent application for binge disorders
-
Clearmind Medicine (CMND) files for 17.02M share offering by selling stockholders
-
Clearmind Medicine secures $10 million financing agreement
-
Clearmind Medicine receives patent publication for obesity therapy
-
Clearmind Medicine files patent for obesity and liver disease therapy
-
Clearmind Medicine initiates clinical site for alcohol disorder trial
-
Clearmind adds Johns Hopkins site to alcohol treatment trial
-
Clearmind Medicine (CMND) Announces IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Tel Aviv Sourasky Medical Center
-
Clearmind Medicine (CMND) Announces First Participant Ever Dosed with its CMND-100 Treatment in Groundbreaking Clinical Trial for Alcohol Use Disorder
-
Clearmind Medicine (CMND) Expands Global Clinical Trial Targeting Multibillion-Dollar Alcohol Use Disorder Market
-
Clearmind Medicine (CMND) Enrolls First Patient in its Clinical Trial for Alcoholism Treatment
-
Clearmind Medicine (CMND) Adds Leading Israeli Clinical Site to Its Ongoing Clinical Trial for Alcohol Use Disorder
-
Clearmind Medicine (CMND) Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics
-
SciSparc (SPRC) -Clearmind (CMND) Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders
-
Clearmind Medicine (CMND) Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders
-
Clearmind Medicine (CMND) Launches First U.S. Clinical Site for its FDA-Approved Clinical Trial to Combat Alcoholism
-
Clearmind Medicine (CMND) Announces the Publication of International Patent Application for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders
-
Clearmind Medicine (CMND) Launches EDC System
-
Clearmind Medicine's (CMND) Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S.
-
Clearmind Medicine (CMND) to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination
-
Clearmind Medicine (CMND) Announces Initiation of First in Human Clinical Trial with CMND-100 in Alcohol Use Disorder Patients
-
Clearmind Medicine (CMND) Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea
-
Clearmind Medicine (CMND) Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico
-
Clearmind Medicine (CMND) Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment
-
SciSparc (SPRC) and Clearmind (CNMD) Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment
-
Clearmind Medicine (CMND) Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute
-
Clearmind Medicine (CMND) Receives IRB Approval for its FDA-Regulated Clinical Trial
-
Clearmind Medicine (CMND) and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in ActivCrystal Format
-
Clearmind Medicine (CMND) Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100
